News on Pfizer (Ticker: PFE) continually updated from thousands of sources around the net.
1 hr ago | Reuters
Shares of the company, which doesn't have any drug in the market, tripled to $176.94 in extended trading.
Trending on the Topix Network
6 hrs ago | Fox News
A top Democrat warned on Tuesday a recent string of so-called tax inversions could foreshadow future moves as U.S. firms look to dodge American taxes.
11 hrs ago | Forbes.com
Watching big pharmaceutical companies and other major U.S. corporations line up to make foreign acquisitions that will bring them a low-tax haven as headquarters, a middle market CEO/owner/entrepreneur could easily become jealous.
The latest tally of analyst opinions from the major brokerage houses shows that among the 30 stocks making up the Dow Jones Industrial Average, Pfizer is the #16 analyst pick.
Consistently, one of the more popular stocks people enter into their stock options watchlist at Stock Options Channel is Pfizer Inc .
Note: We do not store your email address but your IP address will be logged to prevent abuse of this feature.
The Borough of West Chester early this week won the latest episode in a years-long court battle with drugmaker Pfizer over sewer payments owed to the borough by Wyeth, the pharmaceutical company that Pfizer bought in 2009 for $68 billion.
There have been several noteworthy developments in the drug space recently, which will likely have a material impact on the companies in this sector and the markets they serve.
Bristol-Myers Squibb Company And Pfizer Inc. Announce Enrollment Of First Patient In Phase IV EMANATE Trial To Assess Effectiveness And Safety Of Eliquis In Patients With NVAF Undergoing Cardioversion PRINCETON, N.J. & NEW YORK-- --Bristol-Myers Squibb Company and Pfizer Inc. today announced that the first patient has been enrolled into a Phase IV ... (more)
Looking at units outstanding versus one week prior within the universe of ETFs covered at ETF Channel, the biggest outflow was seen in the Health Care Select Sector SPDR Fund , where 4,800,000 units were destroyed, or a 3.0% decrease week over week.
In a Phase 3 clinical tria l comparing Pfizer's BeneFIX Coagulation Factor IX as a treatment for patients with moderately severe-to-severe hemophilia B to on-demand treatment, the once-weekly therapy achieved its primary endpoint of a statistically significant reduction in the annualized bleeding rate versus on-demand.
Net income for the quarter ended June 30, 2014 was $3,873,000 or $1.82 ... )--ISIN XS0179021133 Issuer Name GREENLAND CDO LTD Paying Agent HSBC BANK PLC Redemption Type REPURCHASE Currency EUR O/S Balance 244,020,000.00 New Balance 0 .0... )--FUND A db x-trackers MSCI JAPAN TRN INDEX UCITS ETF DEALING DATE A 15-Jul-14 NAV PER SHARE A USD47.7014 ... (more)
The New York firm has made back roughly 80 percent of its investment in the capsule maker.
Pfizer Announces Positive Top-Line Results From Phase 3 Study Of NONACOG ALFA Once-Weekly Prophylaxis For Hemophilia B - See more at: http://press.pfizer.com/press-release/pfizer-announces-positive-top-line-results-phase-3-study-nonacog-alfa-benefix-once-wee#sthash.YaBu8KgQ.dpuf Once-Weekly Prophylaxis Treatment with BeneFIXA Significantly Reduced ... (more)
We pitch two companies from the pharmaceuticals sector, Pfizer and Novartis, against one another in the latest instalment of our Head-To-Head series.
Updated: Tue Jul 22, 2014 07:43 pm
Copyright © 2014 Topix LLC